Literature DB >> 32552454

Robustness of risk-based allocation of resources for disease prevention.

Mitchell H Gail1, David Pee2.   

Abstract

Risk models for disease incidence can be useful for allocating resources for disease prevention if risk assessment is not too expensive. Assume there is a preventive intervention that should be given to everyone, but preventive resources are limited. We optimize risk-based prevention strategies and investigate robustness to modeling assumptions. The optimal strategy defines the proportion of the population to be given risk assessment and who should be offered intervention. The optimal strategy depends on the ratio of available resources to resources needed to intervene on everyone, and on the ratio of the costs of risk assessment to intervention. Risk assessment is not recommended if it is too expensive. Preventive efficiency decreases with decreasing compliance to risk assessment or intervention. Risk measurement error has little effect nor does misspecification of the risk distribution. Ignoring population substructure has small effects on optimal prevention strategy but can lead to modest over- or under-spending. We give conditions under which ignoring population substructure has no effect on optimal strategy. Thus, a simple one-population model offers robust guidance on prevention strategy but requires data on available resources, costs of risk assessment and intervention, population risk distribution, and probabilities of acceptance of risk assessment and intervention.

Entities:  

Keywords:  Disease prevention; cost constraints; optimal prevention strategy; risk-based resource allocation; robustness of prevention strategy to assumptions

Mesh:

Year:  2020        PMID: 32552454      PMCID: PMC8860617          DOI: 10.1177/0962280220930055

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  16 in total

1.  Fecal occult blood testing when colonoscopy capacity is limited.

Authors:  Janneke A Wilschut; J Dik F Habbema; Monique E van Leerdam; Lieke Hol; Iris Lansdorp-Vogelaar; Ernst J Kuipers; Marjolein van Ballegooijen
Journal:  J Natl Cancer Inst       Date:  2011-11-09       Impact factor: 13.506

2.  American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.

Authors:  Debbie Saslow; Carla Boetes; Wylie Burke; Steven Harms; Martin O Leach; Constance D Lehman; Elizabeth Morris; Etta Pisano; Mitchell Schnall; Stephen Sener; Robert A Smith; Ellen Warner; Martin Yaffe; Kimberly S Andrews; Christy A Russell
Journal:  CA Cancer J Clin       Date:  2007 Mar-Apr       Impact factor: 508.702

Review 3.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

Review 4.  Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.

Authors:  J E Siegel; M C Weinstein; L B Russell; M R Gold
Journal:  JAMA       Date:  1996 Oct 23-30       Impact factor: 56.272

5.  Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension.

Authors:  W B Stason; M C Weinstein
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

6.  Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening.

Authors:  Mitchell H Gail; Ruth M Pfeiffer
Journal:  J Natl Cancer Inst       Date:  2018-09-01       Impact factor: 13.506

7.  Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2009-11-17       Impact factor: 25.391

8.  Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: an evaluation of seven common cancers.

Authors:  Ju-Hyun Park; Mitchell H Gail; Mark H Greene; Nilanjan Chatterjee
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

9.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.

Authors:  Gillian D Sanders; Peter J Neumann; Anirban Basu; Dan W Brock; David Feeny; Murray Krahn; Karen M Kuntz; David O Meltzer; Douglas K Owens; Lisa A Prosser; Joshua A Salomon; Mark J Sculpher; Thomas A Trikalinos; Louise B Russell; Joanna E Siegel; Theodore G Ganiats
Journal:  JAMA       Date:  2016-09-13       Impact factor: 56.272

10.  Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.

Authors:  Nora Pashayan; Steve Morris; Fiona J Gilbert; Paul D P Pharoah
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.